ReviewEndocrine, metabolic & immune disorders drug targets2026
Global Research Trends in Innate Lymphoid Cells in the Gut and Kidney: A Bibliometric and Visual Analysis.
Review in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInnate lymphoid cells (ILCs), critical immune regulators in mucosal tissues, maintain tissue homeostasis, modulate inflammation, and drive immune defense. While their roles in gut and kidney biology are increasingly studied, global research trends and focal points in this field remain largely uncharacterized.
methodsUsing the Web of Science Core Collection (2004-2024), we analyzed 6,835 articles on gut- and kidney-associated ILCs. Bibliometric tools (VOSviewer, CiteSpace) were employed to evaluate publication trends, collaborations, institutional contributions, author influence, journal profiles, and keyword patterns to identify research priorities. Results and Discission: Annual publications surged from 2004 to 2024, peaking at 622 in 2024. The U.S. (2,145 articles), China (1,539), and Germany (679) dominated output, with Harvard Medical School and Inserm as leading institutions. Gregory F. Sonnenberg and David Artis were the most-cited authors. Key journals included
conclusionThis study underscores the therapeutic potential of ILCs in inflammation and cancer within the gut and kidney, advocating for interdisciplinary collaboration to advance mechanistic and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.